Daneng Li1, Christina Darden2, Noran Osman3, Salma Sayeed3, Laurin Jackson2, Diana Garbinsky2, Aman Chauhan4. 1. City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA. 2. RTI Health Solutions, Research Triangle Park, NC, USA. 3. TerSera Therapeutics, Deerfield, IL, USA. 4. Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
Abstract
Background: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor approved for the treatment of carcinoid syndrome diarrhea (CSD) in combination with somatostatin analogs (SSAs). Methods: This prospective, observational, single-arm study evaluated long-term patient-reported outcomes for adults initiating TE in US clinical practice from 2017 through January 2022. The primary objective was satisfaction with overall CS symptom control 6 months after initiating TE. Secondary objectives evaluated satisfaction with control of CSD, flushing, and CS symptoms, as well as work productivity/activity impairment, SSA use, and weight. All analyses were descriptive in nature. Results: A total of 223 patients completed the baseline survey; 56% also completed the 6-month follow-up survey. Mean age was 61 years and 61% were women. After 6 months of TE treatment, the majority of patients (76%, n=95/125) reported being satisfied with control of their CS symptoms which was markedly improved from baseline (41%, n=91). Similarly, the majority of patients (78%, n=97/125) were satisfied with control of their CSD after 6 months of TE, markedly improved from baseline (36%). Conclusion: This longitudinal observational study showed improvements in real-world clinical and humanistic outcomes for patients with CS and at least 6 months of TE treatment.
Background: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor approved for the treatment of carcinoid syndrome diarrhea (CSD) in combination with somatostatin analogs (SSAs). Methods: This prospective, observational, single-arm study evaluated long-term patient-reported outcomes for adults initiating TE in US clinical practice from 2017 through January 2022. The primary objective was satisfaction with overall CS symptom control 6 months after initiating TE. Secondary objectives evaluated satisfaction with control of CSD, flushing, and CS symptoms, as well as work productivity/activity impairment, SSA use, and weight. All analyses were descriptive in nature. Results: A total of 223 patients completed the baseline survey; 56% also completed the 6-month follow-up survey. Mean age was 61 years and 61% were women. After 6 months of TE treatment, the majority of patients (76%, n=95/125) reported being satisfied with control of their CS symptoms which was markedly improved from baseline (41%, n=91). Similarly, the majority of patients (78%, n=97/125) were satisfied with control of their CSD after 6 months of TE, markedly improved from baseline (36%). Conclusion: This longitudinal observational study showed improvements in real-world clinical and humanistic outcomes for patients with CS and at least 6 months of TE treatment.
Authors: C Toumpanakis; J Garland; L Marelli; R Srirajaskanthan; J Soh; P Davies; J Buscombe; M E Caplin Journal: Aliment Pharmacol Ther Date: 2009-07-02 Impact factor: 8.171
Authors: Matthew H Kulke; Dieter Hörsch; Martyn E Caplin; Lowell B Anthony; Emily Bergsland; Kjell Öberg; Staffan Welin; Richard R P Warner; Catherine Lombard-Bohas; Pamela L Kunz; Enrique Grande; Juan W Valle; Douglas Fleming; Pablo Lapuerta; Phillip Banks; Shanna Jackson; Brian Zambrowicz; Arthur T Sands; Marianne Pavel Journal: J Clin Oncol Date: 2016-10-28 Impact factor: 44.544
Authors: Daniel M Halperin; Chan Shen; Arvind Dasari; Ying Xu; Yiyi Chu; Shouhao Zhou; Ya-Chen Tina Shih; James C Yao Journal: Lancet Oncol Date: 2017-02-24 Impact factor: 41.316
Authors: Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold Journal: J Clin Oncol Date: 2009-08-24 Impact factor: 44.544
Authors: Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: Jonathan Strosberg; Vijay N Joish; Susan Giacalone; Raul Perez-Olle; Ann Fish-Steagall; Kanika Kapoor; Sam Dharba; Pablo Lapuerta; Al B Benson Journal: Oncologist Date: 2019-06-12